Tofacitinib (Xeljanz) for the treatment of psoriasis with inflammation of the joints (psoriatic arthritis)

Introduction

Tofacitinib (trade name: Xeljanz) has been approved in Germany since June 2018 for the systemic treatment of psoriatic arthritis in adults. It is an option for adults with active psoriatic arthritis who did not benefit enough from – or who did not tolerate – antirheumatic medication. Tofacitinib is used in combination with methotrexate.

Psoriatic arthritis is a condition that leads to pain and stiffness in joints. It can be caused by psoriasis, but sometimes occurs in people who don't have any visible psoriasis-related skin changes.

It is estimated that 20% of people who have psoriasis also develop pain and in their joints at some point. The joints start hurting and may feel stiff for a while, particularly in the morning.

Psoriatic arthritis can occur in many joints of the body. It often affects the hands, feet, elbows, knees, back of the neck or vertebrae (bones in the spine). More than five joints typically become inflamed, including the joints at the end of the fingers and toes. These joints are especially prone to becoming deformed in severe cases. Tendons and tendon sheaths can also become inflamed.

Treatment with tofacitinib aims to relieve reduce the of in the joints by inhibiting a protein, thereby reducing the production of several chemical messengers that promote .

Application

Tofacitinib is taken twice a day in tablet form. One tablet contains 5 mg of tofacitinib.

Other treatments

For patients with psoriatic arthritis who did not benefit enough from – or who cannot tolerate treatment with – disease-modifying antirheumatic medication, treatment with a tumor necrosis factor (TNF) α inhibitor is an option. This treatment can be combined with methotrexate.

For patients with psoriatic arthritis who did not benefit enough from – or who cannot tolerate – treatment with one particular disease-modifying biological disease-modifying antirheumatic drugs (bDMARD), treatment with a different disease-modifying biological antirheumatic drug (bDMARD) is an option. This treatment can be combined with methotrexate.

Assessment

In 2018, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into whether tofacitinib for the treatment of psoriatic arthritis has any advantages or disadvantages compared with the standard treatments for the treatment of psoriatic arthritis for in adults who did not benefit from or who cannot tolerate treatment with antirheumatic medication.

But the manufacturer didn’t provide any suitable data with which to do the assessment.

More information

This information summarizes the main results of a review produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The review was commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of the review and the hearings received, the G-BA passed a resolution on the added benefit of tofacitinib (Xeljanz).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Tofacitinib (psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A18- 51. November 28, 2018. (IQWiG reports; Volume 681).

IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.

Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.

Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.

Comment on this page

What would you like to share with us?

We welcome any feedback and ideas. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.

Please note that we do not provide individual advice on matters of health. You can read about where to find help and support in Germany in our information “How can I find self-help groups and information centers?

Updated on January 3, 2019
Next planned update: 2022

Authors/Publishers:

Institute for Quality and Efficiency in Health Care (IQWiG, Germany)

How we keep you informed

Follow us on Twitter or subscribe to our newsletter or newsfeed. You can find all of our films online on YouTube.